Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOEP Induction and Gem/Bu/Mel ASCT for T-Cell Lymphoma
NCT01746173Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, busulfan and melphalan in peripheral T-cell lymphoma (PTCL), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Progression-Free Survival at 24 months. Started Jul 2013; status: terminated.
02
Drugs
gemcitabinebusulfanmelphalan
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT01746173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01746173.